• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature . Defining the risk of SARS-CoV-2 variants on immune protection

tetano

Editor, Senior Moderator
Nature


. 2022 Mar 31.
doi: 10.1038/s41586-022-04690-5. Online ahead of print.
Defining the risk of SARS-CoV-2 variants on immune protection


Marciela M DeGrace[SUP] #[/SUP][SUP] 1 2 [/SUP], Elodie Ghedin[SUP] #[/SUP][SUP] 1 3 [/SUP], Matthew B Frieman[SUP] #[/SUP][SUP] 4 [/SUP], Florian Krammer[SUP] #[/SUP][SUP] 5 6 [/SUP], Alba Grifoni[SUP] #[/SUP][SUP] 7 [/SUP], Arghavan Alisoltani[SUP] 8 [/SUP], Galit Alter[SUP] 9 [/SUP], Rama R Amara[SUP] 10 [/SUP], Ralph S Baric[SUP] 11 12 [/SUP], Dan H Barouch[SUP] 13 [/SUP], Jesse D Bloom[SUP] 14 [/SUP], Louis-Marie Bloyet[SUP] 15 [/SUP], Gaston Bonenfant[SUP] 16 [/SUP], Adrianus C M Boon[SUP] 17 [/SUP], Eli A Boritz[SUP] 1 2 18 [/SUP], Debbie L Bratt[SUP] 1 2 19 [/SUP], Traci L Bricker[SUP] 17 [/SUP], Liliana Brown[SUP] 1 2 [/SUP], William J Buchser[SUP] 20 [/SUP], Juan Manuel Carreño[SUP] 21 [/SUP], Liel Cohen-Lavi[SUP] 22 [/SUP], Tamarand L Darling[SUP] 17 [/SUP], Meredith E Davis-Gardner[SUP] 23 [/SUP], Bethany L Dearlove[SUP] 24 [/SUP], Han Di[SUP] 16 [/SUP], Meike Dittmann[SUP] 25 [/SUP], Nicole A Doria-Rose[SUP] 1 18 [/SUP], Daniel C Douek[SUP] 1 18 [/SUP], Christian Drosten[SUP] 26 [/SUP], Venkata-Viswanadh Edara[SUP] 23 [/SUP], Ali Ellebedy[SUP] 27 [/SUP], Thomas P Fabrizio[SUP] 28 [/SUP], Guido Ferrari[SUP] 29 [/SUP], William C Florence[SUP] 1 2 [/SUP], Ron A M Fouchier[SUP] 30 [/SUP], John Franks[SUP] 28 [/SUP], Adolfo García-Sastre[SUP] 21 31 32 33 34 [/SUP], Adam Godzik[SUP] 8 [/SUP], Ana Silvia Gonzalez-Reiche[SUP] 35 [/SUP], Aubree Gordon[SUP] 36 [/SUP], Bart L Haagmans[SUP] 30 [/SUP], Peter J Halfmann[SUP] 37 [/SUP], David D Ho[SUP] 38 [/SUP], Michael R Holbrook[SUP] 39 [/SUP], Yaoxing Huang[SUP] 38 [/SUP], Sarah L James[SUP] 40 [/SUP], Lukasz Jaroszewski[SUP] 8 [/SUP], Trushar Jeevan[SUP] 28 [/SUP], Robert M Johnson[SUP] 4 [/SUP], Terry C Jones[SUP] 26 40 [/SUP], Astha Joshi[SUP] 17 [/SUP], Yoshihiro Kawaoka[SUP] 37 41 42 [/SUP], Lisa Kercher[SUP] 43 [/SUP], Marion P G Koopmans[SUP] 30 [/SUP], Bette Korber[SUP] 44 [/SUP], Eilay Koren[SUP] 22 45 [/SUP], Richard A Koup[SUP] 1 18 [/SUP], Eric B LeGresley[SUP] 40 [/SUP], Jacob E Lemieux[SUP] 46 [/SUP], Mariel J Liebeskind[SUP] 20 [/SUP], Zhuoming Liu[SUP] 15 [/SUP], Brandi Livingston[SUP] 43 [/SUP], James P Logue[SUP] 4 [/SUP], Yang Luo[SUP] 38 [/SUP], Adrian B McDermott[SUP] 1 18 [/SUP], Margaret J McElrath[SUP] 47 [/SUP], Victoria A Meliopoulos[SUP] 43 [/SUP], Vineet D Menachery[SUP] 48 [/SUP], David C Montefiori[SUP] 49 [/SUP], Barbara Mühlemann[SUP] 26 40 [/SUP], Vincent J Munster[SUP] 50 [/SUP], Jenny E Munt[SUP] 11 [/SUP], Manoj S Nair[SUP] 38 [/SUP], Antonia Netzl[SUP] 40 [/SUP], Anna M Niewiadomska[SUP] 51 [/SUP], Sijy O'Dell[SUP] 1 18 [/SUP], Andrew Pekosz[SUP] 52 [/SUP], Stanley Perlman[SUP] 53 [/SUP], Marjorie C Pontelli[SUP] 15 [/SUP], Barry Rockx[SUP] 30 [/SUP], Morgane Rolland[SUP] 24 [/SUP], Paul W Rothlauf[SUP] 15 [/SUP], Sinai Sacharen[SUP] 22 45 [/SUP], Richard H Scheuermann[SUP] 51 [/SUP], Stephen D Schmidt[SUP] 1 18 [/SUP], Michael Schotsaert[SUP] 21 34 [/SUP], Stacey Schultz-Cherry[SUP] 43 [/SUP], Robert A Seder[SUP] 1 18 [/SUP], Mayya Sedova[SUP] 8 [/SUP], Alessandro Sette[SUP] 7 54 [/SUP], Reed S Shabman[SUP] 1 2 [/SUP], Xiaoying Shen[SUP] 29 [/SUP], Pei-Yong Shi[SUP] 55 [/SUP], Maulik Shukla[SUP] 56 57 [/SUP], Viviana Simon[SUP] 21 31 32 34 [/SUP], Spencer Stumpf[SUP] 15 [/SUP], Nancy J Sullivan[SUP] 1 18 [/SUP], Larissa B Thackray[SUP] 58 [/SUP], James Theiler[SUP] 44 [/SUP], Paul G Thomas[SUP] 59 [/SUP], Sanja Trifkovic[SUP] 28 [/SUP], Sina Türeli[SUP] 40 [/SUP], Samuel A Turner[SUP] 40 [/SUP], Maria A Vakaki[SUP] 20 [/SUP], Harm van Bakel[SUP] 35 [/SUP], Laura A VanBlargan[SUP] 58 [/SUP], Leah R Vincent[SUP] 1 2 [/SUP], Zachary S Wallace[SUP] 60 61 [/SUP], Li Wang[SUP] 16 [/SUP], Maple Wang[SUP] 38 [/SUP], Pengfei Wang[SUP] 38 [/SUP], Wei Wang[SUP] 62 [/SUP], Scott C Weaver[SUP] 48 [/SUP], Richard J Webby[SUP] 28 [/SUP], Carol D Weiss[SUP] 62 [/SUP], David E Wentworth[SUP] 16 [/SUP], Stuart M Weston[SUP] 4 [/SUP], Sean P J Whelan[SUP] 15 [/SUP], Bradley M Whitener[SUP] 58 [/SUP], Samuel H Wilks[SUP] 40 [/SUP], Xuping Xie[SUP] 55 [/SUP], Baoling Ying[SUP] 58 [/SUP], Hyejin Yoon[SUP] 44 [/SUP], Bin Zhou[SUP] 16 [/SUP], Tomer Hertz[SUP] 63 [/SUP], Derek J Smith[SUP] 64 [/SUP], Michael S Diamond[SUP] 65 [/SUP], Diane J Post[SUP] 66 67 [/SUP], Mehul S Suthar[SUP] 68 [/SUP]



Affiliations

Abstract

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced following infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH) established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) program. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants potentially impacting transmission, virulence, and resistance to convalescent and vaccine-induced immunity. The SAVE program serves as a critical data-generating component of the United States Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines, and therapeutics and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity, and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.
 
Back
Top Bottom